Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

Novel therapeutics for type 2 diabetes: insulin resistance.

Diabetes, obesity & metabolism·2014
Same author

What factors influence concordance with medications? Findings from the U.K. Asian Diabetes study.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.

Diabetes, obesity & metabolism·2014
Same author

Incidence, worry and discussion about dosing irregularities and self-treated hypoglycaemia amongst HCPs and patients with type 2 diabetes: results from the UK cohort of the Global Attitudes of Patient and Physicians (GAPP2) survey.

International journal of clinical practice·2014
Same author

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

Diabetes, obesity & metabolism·2013

Related Experiment Video

Updated: Jun 7, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Bromocriptine: old drug, new formulation and new indication.

R I G Holt1, A H Barnett, C J Bailey

  • 1Endocrinology and Metabolism Sub-division, Developmental Origins of Adult Health and Disease Division, University of Southampton School of Medicine, Southampton, UK. righ@soton.ac.uk

Diabetes, Obesity & Metabolism
|October 28, 2010
PubMed
Summary

Quick-release bromocriptine, taken in the morning, helps manage type 2 diabetes by resetting circadian rhythms. This new treatment improves insulin resistance and lowers blood sugar levels effectively.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jun 7, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Endocrinology
  • Neuroscience
  • Metabolic Disorders

Background:

  • Hypothalamic hypodopaminergic states and disrupted circadian rhythms are linked to insulin resistance, obesity, and diabetes.
  • Bromocriptine, a dopamine D(2) receptor agonist, has historical uses in hyperprolactinemia, galactorrhea, and Parkinsonism.

Purpose of the Study:

  • To evaluate the efficacy of a quick-release (QR) bromocriptine formulation in managing type 2 diabetes mellitus (T2DM).
  • To investigate the potential of QR-bromocriptine to reset circadian rhythms and improve metabolic abnormalities.

Main Methods:

  • Administration of QR-bromocriptine in the early morning during the light phase.
  • Clinical studies (Phase II and III) involving patients with T2DM, assessing glycated haemoglobin levels.
  • Evaluation of safety and tolerability, including comparison with doses used for Parkinson's disease.

Main Results:

  • QR-bromocriptine lowered glycated haemoglobin by 0.6-1.2% (7-13 mmol/mol) as monotherapy or adjunct therapy.
  • The drug was generally well-tolerated, with nausea being the primary side effect.
  • Lower doses used for T2DM did not show associations with retroperitoneal fibrosis or heart valve abnormalities.

Conclusions:

  • A morning-timed QR-bromocriptine formulation offers a novel, neurally mediated approach for hyperglycaemia control in T2DM.
  • QR-bromocriptine (Cycloset™) is approved in the USA for treating T2DM, demonstrating significant improvements in glycemic control.